Stockscreener 앱 받기
1.44
1.37%
-0.02
시간 외 거래:
1.45
0.01
+0.69%
Soligenix Inc 주식(SNGX)의 최신 뉴스
Can Soligenix Inc. stock double in next 5 years2025 Key Highlights & Low Volatility Stock Suggestions - ulpravda.ru
Can Soligenix Inc. stock maintain growth trajectory2025 Technical Overview & Consistent Profit Alerts - ulpravda.ru
Options Flow: Why Soligenix Inc. stock is trending among retail traders - ulpravda.ru
Is Soligenix Inc. (DOA0) stock a safe buy pre earnings2025 AllTime Highs & Growth Focused Entry Point Reports - ulpravda.ru
How Soligenix Inc. stock benefits from strong dollarPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Why Soligenix Inc. stock is trending among retail tradersTrade Entry Summary & Reliable Entry Point Trade Alerts - ulpravda.ru
How strong is Soligenix Inc. stock balance sheetWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Soligenix Completes Key Phase 2 Psoriasis Trial, Setting the Stage for SGX302 Data - TipRanks
Ideas Watch: Can Soligenix Inc stock double in next 5 yearsWeekly Trend Recap & Verified Momentum Stock Watchlist - moha.gov.vn
What drives Soligenix Inc DOA0 stock priceMerger & Acquisition Updates & Buy Sell Timing Alerts - earlytimes.in
Tech Rally: Is Soligenix Inc stock overvalued by current metricsLong Setup & Daily Technical Forecast Reports - moha.gov.vn
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - Digital Journal
SNGX: Positive Results for Phase 2a Trial in Psoriasis - Research Tree
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease - Indian Pharma Post
Gains Recap: Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Is Soligenix Inc. stock cheap at current valuationQuarterly Profit Summary & Smart Money Movement Tracker - Улправда
Alliance Global Partners Sticks to Its Buy Rating for Soligenix (SNGX) - The Globe and Mail
Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Institution Moves: Will Soligenix Inc. (DOA0) stock beat Nasdaq index returnsJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - DonanımHaber
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behcet's Disease - Digital Journal
Soligenix reports positive results from SGX945 trial for Behçet’s disease By Investing.com - Investing.com Nigeria
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease - Barchart.com
Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology - marketscreener.com
Soligenix shares jump on encouraging data for Behçet’s disease therapy - MSN
Soligenix stock rises after positive Behçet’s Disease treatment data By Investing.com - Investing.com Nigeria
Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com India
Soligenix (SNGX) Shows Promising Results in Phase 2a Behcet's Di - GuruFocus
Soligenix reports positive results from SGX945 trial for Behçet’s disease - Investing.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the T - GuruFocus
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford) - Finviz
Positive clinical results from phase 2 trial of SGX945 - marketscreener.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - Fidelity
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) – Company AnnouncementFT.com - Financial Times
Soligenix (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis - Digital Journal
Soligenix reports positive results from psoriasis gel treatment trial By Investing.com - Investing.com Nigeria
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
Soligenix Announces Top-line Results of the Phase 2a Study of SG - GuruFocus
Soligenix reports positive results from psoriasis gel treatment trial - Investing.com
Soligenix announces top-line results of the phase 2a study of SGX302 - marketscreener.com
Soligenix (SNGX) Reports Promising Phase 2a Results for Psoriasis Treatment - GuruFocus
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis – Company AnnouncementFT.com - Financial Times
[Form 4] SOLIGENIX, INC. Insider Trading Activity - Stock Titan
Soligenix (NASDAQ: SNGX) awards CFO 100,000 options at $ 1.63 strike - Stock Titan
Soligenix (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies - Digital Journal
Soligenix’s HyBryte Therapy Advances as Rare Disease Treatment Gap Grows - citybuzz
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) on - GlobeNewswire
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone - Digital Journal
0.80%
4.56%
자본화:
|
볼륨(24시간):